← Back to Screener
Xenon Pharmaceuticals Inc (XENE)
Price$58.43
Favorite Metrics
Price vs S&P 500 (26W)46.03%
Price vs S&P 500 (4W)1.10%
Market Capitalization$5.47B
All Metrics
Book Value / Share (Quarterly)$7.27
P/TBV (Annual)2.63x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-7.35%
Cash Flow / Share (Quarterly)$-3.50
Price vs S&P 500 (YTD)28.73%
Net Profit Margin (TTM)-867.29%
EPS (TTM)$-4.36
10-Day Avg Trading Volume0.91M
EPS Excl Extra (TTM)$-4.36
Revenue Growth (5Y)-25.27%
EPS (Annual)$-4.36
ROI (Annual)-59.46%
Net Profit Margin (5Y Avg)-1413.62%
Cash / Share (Quarterly)$6.86
ROA (Last FY)-54.63%
EBITD / Share (TTM)$-4.68
ROE (5Y Avg)-28.38%
Operating Margin (TTM)-969.84%
Cash Flow / Share (Annual)$-3.50
P/B Ratio9.41x
P/B Ratio (Quarterly)6.09x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)703.43x
Net Interest Coverage (TTM)-38.23x
ROA (TTM)-52.04%
EPS Incl Extra (Annual)$-4.36
Current Ratio (Annual)13.42x
Quick Ratio (Quarterly)13.17x
3-Month Avg Trading Volume1.22M
52-Week Price Return76.08%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$9.79
P/S Ratio (Annual)729.99x
Asset Turnover (Annual)0.01x
52-Week High$63.95
Operating Margin (5Y Avg)-1499.88%
EPS Excl Extra (Annual)$-4.36
CapEx CAGR (5Y)-21.26%
Tangible BV CAGR (5Y)82.20%
26-Week Price Return50.01%
Quick Ratio (Annual)13.17x
13-Week Price Return42.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.42x
Enterprise Value$5,275.734
Revenue / Share Growth (5Y)-36.71%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)8.23%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4598.59%
Cash / Share (Annual)$6.86
3-Month Return Std Dev103.20%
Net Income / Employee (TTM)$-1
ROE (Last FY)-59.46%
Net Interest Coverage (Annual)-22.77x
EPS Basic Excl Extra (Annual)$-4.36
Receivables Turnover (TTM)5.28x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.36
Receivables Turnover (Annual)5.28x
ROI (TTM)-55.81%
P/S Ratio (TTM)729.99x
Pretax Margin (5Y Avg)-1410.90%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$11.53
Price vs S&P 500 (52W)46.25%
Year-to-Date Return31.37%
5-Day Price Return0.49%
EPS Normalized (Annual)$-4.36
ROA (5Y Avg)-26.66%
Net Profit Margin (Annual)-4612.13%
Month-to-Date Return1.26%
Cash Flow / Share (TTM)$-2.61
EBITD / Share (Annual)$-4.68
Operating Margin (Annual)-4974.27%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-28.38%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.36
P/TBV (Quarterly)2.98x
P/B Ratio (Annual)6.09x
Pretax Margin (TTM)-861.60%
Book Value / Share (Annual)$7.27
Price vs S&P 500 (13W)42.12%
Beta0.73x
P/FCF (Annual)121.56x
Revenue / Share (TTM)$0.09
ROE (TTM)-55.81%
52-Week Low$28.19
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.35
4.37
4.38
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XENEXenon Pharmaceuticals Inc | 729.99x | — | — | — | $58.43 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Xenon Pharmaceuticals is a biopharmaceutical company developing novel treatments for neurological and psychiatric disorders, including epilepsy, depression, and pain. The company's pipeline includes three epilepsy candidates—XEN1101, NBI-921352, and XEN496—as well as oral Nav1.7 inhibitors for pain management. It targets areas with significant unmet medical need in neuroscience.